Applications to the Fiscal
Year 2016 (FY16) Neurofibromatosis Research Program (NFRP) are
being solicited by the U.S. Army Medical Research Acquisition Activity
(USAMRAA). The managing agent for this Program Announcement/Funding Opportunity
is the Congressionally Directed Medical Research Programs (CDMRP). The NFRP was
initiated in 1996 to provide support for research of exceptional scientific
merit that promotes the understanding, diagnosis, and treatment of
neurofibromatosis (NF) including NF type 1 (NF1) and type 2 (NF2) and
schwannomatosis. Appropriations for the NFRP from FY96 through FY15 totaled
$287.85 million (M). The FY16 appropriation is $15.0M.
FY16 NFRP Vision: The
vision of the FY16 NFRP is to decrease the clinical impact of neurofibromatosis.
To this end, the NFRP seeks to support innovative, high-impact research that
will foster new directions for and address neglected issues in NF research;
sponsor multidisciplinary and multi-institutional collaborations that will
bring new perspectives to the field; promote translational and clinical studies
to move promising ideas from bench to bedside; and develop a balanced portfolio
of meritorious research related to all aspects of NF1, NF2, and
schwannomatosis.
FY16 NFRP Program Announcements and General Application
Instructions for the following award mechanisms are posted on the Grants.gov website.
Clinical
Consortium Award
The Operations Center PI must be an independent investigator at
or above the level of Associate Professor (or equivalent) with experience in
developing and running large scale initiatives such as clinical trials or consortia.
· Support
consortium that will conceive, design, develop, and conduct collaborative Phase
I, and II clinical evaluations of promising therapeutic agents for the
management or treatment of NF1, NF2, and schwannomatosis.
· Open
to any group of institutions with a demonstrated history of collaborative NF
research
All applications must include letters of intent for conducting
a minimum of four clinical trials including at least one NF1-
and one NF2-focused study; two studies must be initiated within the first year
of the award.
· The
maximum period of performance is 4 years.
· The
maximum allowable funding for the entire period of performance is $9,000,000 in
total costs.
· Indirect
costs may be proposed in accordance with your institution’s negotiated rate
agreement.
Note that only $5M total funding (direct and indirect costs)
allocated for this award will be from the FY16 NFRP budget; the balance is
contingent upon receipt of sufficient congressional appropriations to the NFRP
in FY17 and FY18
Clinical Trial Award
Must be at or above the level of
Assistant Professor (or equivalent).
· Supports
research with the potential to have a major impact on the treatment or
management of NF.
· Funds
Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis.
Combinations of phases are permitted.
Must support a clinical trial and may not be
used for preclinical research studies.
· The
maximum period of performance is 4 years.
· The
maximum allowable funding for the entire period of performance is $900,000 in
direct costs.
Indirect costs may be proposed in accordance with the
institution’s negotiated rate agreement.
Exploration – Hypothesis Development Award
Investigators at all academic levels (or equivalent)
· Supports
the initial exploration of innovative, high-risk, high-gain concepts and
potentially groundbreaking concepts in NF research.
· Preliminary
and/or published data encouraged but not required.
· Projects
involving human subjects or human anatomical substances must be exempt under
32 CFR 219.101(b) or eligible for expedited review under 32 CFR
219.110 or 21 CFR 56.110.
Clinical trials not allowed.
· The
maximum period of performance is 2 years.
· The
maximum allowable funding for the entire period of performance is $100,000 in
direct costs.
Indirect costs may be proposed in accordance with the
institution’s negotiated rate agreement.
Investigator-Initiated Research Award
Principal Investigator (PI): Must be at
or above the level of Assistant Professor (or equivalent).
Optional Qualified Collaborator:
Must be at or above the level of Assistant Professor
(or equivalent) and must plan to contribute at least a 10% level of effort for each
budget period for the entirety of the award.
· Supports highly
rigorous, high impact research with the potential to make an important
contribution to NF research and/or patient care.
· Preliminary
and/or published data required.
· Optional
Qualified Collaborator: Applications that include a Qualified
Collaborator who meets criteria identified in the Program Announcement/
Funding Opportunity may apply for a higher level of funding.
Funding Opportunity may apply for a higher level of funding.
Clinical trials not allowed.
· The maximum period of
performance is 3 years.
· The maximum allowable
funding for the entire period of performance is $525,000 in
direct costs ($575,000 in direct costs if requesting an Optional
Qualified Collaborator).
Indirect costs may be proposed in accordance with the
institution’s negotiated rate agreement.
New Investigator Award
Must be either an
independent investigator at or below the level of
Assistant Professor (or equivalent) or an established
independent investigator in an area other than NF at or above the
level of Assistant Professor seeking to transition into a career in NF
research.
To be eligible, applicants
may not have received more than $300,000 in direct costs for NF research as a
PI of one or more Federally funded, non-mentored peer reviewed
grants.
PI must demonstrate a commitment of at least 10% effort toward
the proposed NF research project.
· Supports
the continued development of promising independent investigators and/or the transition
of established investigators from other research fields into a career in NF
research.
· Prior
experience in NF research is not required.
· Preliminary
and/or published data relevant to NF and the proposed research project is
required.
· The maximum period of
performance is 3 years.
· The maximum allowable
funding for the entire period of performance is $450,000 in
direct costs.
Indirect costs may be proposed in accordance with the
institution’s negotiated rate agreement.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s
single-entry portal, Grants.gov. For
email notification when Program Announcements are released go to the CDMRP
website (http://cdmrp.army.mil)
and select Subscribe to Funding Opportunities & Program
Communications. For more information about the NFRP or other
CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
For questions about the research
programs, please contact the MRO Research Grants & Contracts Team (adm-researchgrants.contracts@monash.edu).
No comments:
Post a Comment